Breast Cancer Clinical Trials in Detroit

Showing 241-260 of 609 trials

FPA150 in Patients With Advanced Solid Tumors

NCT03514121

This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.

Breast CancerOvarian CancerEndometrial Cancer+1 more

Five Prime Therapeutics, Inc.95 participantsStarted Mar 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +15 more locations

RECRUITING30 miles

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

TNBC - Triple-Negative Breast CancerMinimal Residual Disease

Personalis Inc.422 participantsStarted Nov 2023

Tucson, Arizona, United States • Aurora, Colorado, United States • Washington D.C., District of Columbia, United States +11 more locations

FPA150 in Patients With Advanced Solid Tumors

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Breast Cancer Trials in Other Cities

The OPBC-07/microNAC Study

Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Comprehensive Outcomes for After Cancer Health

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Other Conditions in Detroit